Essity stock faces PFAS lawsuit over Carefree panty liners

Published on 11/02/2026 at 14:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Essity stock faces legal risk after California residents sued over Carefree liners allegedly containing PFOA. Essity rejects the claim.

Legal risk meets portfolio integration

Hundreds of California residents accuse Essity and other companies over Carefree panty liners allegedly containing PFOA.
Essity rejects the central allegation and says it does not intentionally add PFAS chemicals to Carefree products.
The case adds compliance and potential legal-cost risk as Essity integrates its North American feminine care business.

Essity B, SE0009922164, Illustration mit AI erstellt.

Essity faces legal scrutiny in its North American feminine care business after hundreds of Los Angeles County residents sued over Carefree panty liners. A Manufacturing Dive report carried by Yahoo said court documents were filed on October 9, 2026.

California lawsuit raises compliance risk

The plaintiffs accuse Essity, Edgewell and Johnson & Johnson of manufacturing and distributing Carefree products allegedly made with perfluorooctanoic acid, or PFOA, a chemical in the PFAS group. They also name Gelson's Markets and allege violations of California restrictions on menstrual products intentionally made with PFAS that took effect on January 1, 2025.

The lawsuit cites an independent laboratory test from 2024 that allegedly found PFOA in one or more of five Carefree product layers. The health and product allegations remain unproven in court, and the filing does not establish liability.

Company disputes central allegation

Essity spokesperson Amy Bellcourt said Carefree stands behind its products and that the company does not intentionally add PFAS chemicals to them. She said PFAS are not an ingredient used in making Carefree products, that ingredients are printed on the packaging and that Essity intends to respond vigorously.

Essity completed its acquisition of Edgewell's North American feminine care business on February 4, 2026. The portfolio included Carefree, making the litigation relevant to product compliance, reputation and potential legal costs during the integration.

Investor focus remains on integration

The next material developments are Essity's response, the court's handling of the claims and evidence concerning the products at issue. Investors may also weigh whether the dispute affects the operating outlook for the acquired business.

Essity stock traded at 25.43 euros on Lang & Schwarz at 14:42:50 CET on Monday, November 2, 2026; see the real-time quote of Essity stock.